Why the study?
Data on oral anticoagulant-related intracerebral hemorrhage incidence are scarce, and most time-trend studies predate the introduction of direct oral anticoagulants.
Has the incidence of total and OAC-related intracerebral hemorrhage changed over the past decade following the introduction of DOACs?
Has the incidence of total and OAC-related intracerebral hemorrhage changed over the past decade following the introduction of DOACs?
The incidence of both total and OAC-related intracerebral hemorrhage significantly decreased over the past decade in the Netherlands, coinciding with the introduction of DOACs and improved cardiovascular risk management.
Answers are grounded in this paper and cite their sources.
Declining OAC-related ICH incidence despite rising use may reassure on safety; leaves open causality in observational data.
Background: Data on oral anticoagulant-related (OAC) intracerebral hemorrhage (ICH) incidence are scarce. Most studies on incidence time trends were performed before the introduction of Direct Oral Anticoagulants (DOACs). Between 2008 and 2018, the number of OAC-users in the Netherlands increased by 63%, with the number of DOAC-users almost equaling that of Vitamin K Antagonists (VKA)-users. We aimed to determine the recent total and OAC-related ICH incidence and assess changes over the last decade, including the effect of DOAC introduction. Methods: All adult non-traumatic ICH patients presenting in any of three hospitals in the enclosed region of South-Limburg, the Netherlands, were retrospectively included, during two 3-year time periods: 2007-2009 and 2017-2019. OAC-related ICH was defined as ICH in patients using VKAs or DOACs. We calculated the incidence rate ratio (IRR) between the two study periods. Results: In the 2007-2009 period, we registered 652 ICHs of whom 168 (25.8%) were OAC-related (all VKA). In the 2017-2019 period, we registered 522 ICHs, 121 (23.2%) were OAC-related (70 VKA and 51 DOAC). In 2007-2009, the annual incidence of total ICH and OAC-related ICH was 40.9 and 10.5 per 100,000 person-years, respectively, which decreased to 32.4 and 7.5 per 100,000 person-years in 2017-2019. The IRR for total ICH and OAC-related ICH was 0.67 (95%-CI: 0.60-0.75) and 0.58 (0.46-0.73), respectively. Conclusion: Both total ICH and OAC-related ICH incidence decreased over the past decade in South-Limburg, the Netherlands, despite the aging population and increasing number of OAC-users. The introduction of DOACs, and possibly an improved cardiovascular risk management and change in OAC prescription pattern, could explain these findings.
No takes yet. Share an insight, caveat, or question.
Peeters et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: